SKIP TO CONTENT
About Abbott
Contact
International | eng
Country Language

CARDIOVASCULAR

International | eng
Country Language

XIENCE™ Family of Drug-Eluting Stents

The World's Leading Drug-Eluting Stents (DES), with Unparalleled Clinical Outcomes¹

XIENCE™ Family of Drug-Eluting Stents
Complex Patients

Optimal Outcomes in Complex Patients

Reproducible outcomes are a proven part of XIENCE™ DES performance, delivering consistent patient safety with low complication rates. As a result, XIENCE™ Stent can treat lesions of any complexity in patients with a range of challenging comorbidities1

Increasingly Complex Patients Now Treated with PCI

Complex lesions and increasingly complex percutaneous coronary intervention (PCI) cases compose an ever-growing segment of the patient population, and stenting for these populations may expand in the future.

Even when patients are complex, choosing a stent shouldn't be. XIENCE Skypoint™ Stent is an excellent choice for complex patients2-5 given its best-in-class deliverability6 and expanded treatment options7.

18% of patients undergoing an angiogram have a CTO
40% of PCI are of high bleeding risk
25% of patients receiving a stent have diabetes

XIENCE™ Stent for CTO Lesions

XIENCE™ Stent, the world’s leading DES, is considered by industry experts to be the gold standard.8 It offers unmatched consistency and optimal acute outcomes in all types of patients and lesions, including complex cases.9,10

18% of patients undergoing an angiogram have a CTO
0.3% acute definite ST

XIENCE™ Stent Complex Patient Data: Consistently Low Stent Thrombosis Rates11-16

Results from a number of multicenter, randomized trials show that XIENCE™ Stent has low stent thrombosis (ST) rates, from 30 days to 5 years.
 

left main chart
CTO chart
Bifurcations chart
Diabetes chart
STEMI chart
Short DAPT chart

* DAPT duration of 1 month

 

 

XIENCE™ Stent in All-Comer Complex Patient Population

In a meta-analysis of all-comer complex patients, XIENCE™ Stent was shown to save lives compared to bare metal stents (BMS).17

2-Year Clinical Outcomes: XIENCE™ Stent vs Bare Metal Stents17
 

Fatal Myocardial Infarction

myocardial infarction chart comparison

XIENCE™ Stent results in an 89% risk reduction

Primary Endpoint: Cardiac Death

primary endpoint comparison chart

XIENCE™ Stent results in a 33% risk reduction vs BMS

Myocardial InfarctionBMS (%)DES (%)p value (non-adjusted)p value (†adjusted)
All5.6%4.0%0.010.01
Non-fatal4.8%3.9%0.120.12
Fatal0.8%0.1%0.0030.004


†Adjusted for clinical syndrome (ie, acute coronary syndrome vs stable syndrome), history of diabetes mellitus, female sex, use of glycoprotein IIb/IIIa inhibitors, and up to 1 year vs longer duration of DAPT.

“The benefit of [XIENCE™ Stents] occurred immediately after implantation and . . . also at long-term follow-up beyond 2 years.”
—Manel Sabaté, MD, on the EXAMINATION trial's lower event rates for XIENCE™ Stent versus bare metal stents in STEMI patients15


Detailed Data on Complex Patients, Complex Lesions

XIENCE™ Stent is increasingly used—and evaluated via clinical trials—in complex patients and when treating complex lesions. View more data on complex patients: short DAPT and AMI.

Manuals & Technical Resources

Manuals & Technical Resources

Order Cardiovascular Products

Cardiovascular Products

Customer Service

Customer Service

References

  1. Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Data on file at Abbott.
  2. Shaw JE, et al. Diabetes Res Clin Pract. 2010;87:4-14.
  3. Fefer P, et al. J Am Coll Cardiol. 2012;59(11):991-997.
  4. Capodanno D, et al. J Am Coll Cardiol. 2020;76:1468–1483.
  5. Armstrong E, et al. J Diabetes Sci Technol. 2014;8(3):581–589.
  6. Data on file at Abbott. Bench test data shows XIENCE Skypoint™ Stent (3.0 x 18 mm, n=5) performance compared to Resolute Onyx‡ (3.0 x 18mm, n=5) , SYNERGY MONORAIL‡ (3.0 x 20 mm, n=5) , Promus Elite‡ (3.0 x 20 mm, n=5) , BIOFREEDOM‡ (3.0 x 18 mm, n=5), Resolute Onyx‡ (3.0 x 18 mm, n=5) and ORSIRO‡ (3.0 x 18 mm, n=5). Bench test results may not necessarily be indicative of clinical performance. Catheter test measures average force to cross a challenging lesion model. XIENCE Skypoint™ Stent performed better in crossability and was not statistically different in trackability and pushability.
  7. Instructions for Use – XIENCE Skypoint™ Stent – increased maximum expansion compared to XIENCE Sierra™ Stent.
  8. Data on file at Abbott – XIENCE™ Stent data includes 120 clinical trials, 10+ years of data, 125,000 patients studied, 20,000,000 implants as of Q4 2022 and is the most implanted DES worldwide.
  9. Saito S, et al. EuroIntervention. 2019;15(11):e1006-e1013. Saito S, et al. Eur Heart J. 2014;35:2021-2031. Natsuaki M, et al. J Am Coll Cardiol. 2013;62:181-190. Stone G, et al. TCT 2017 – ABSORB IV. Note: 99% is the lowest device success rate.
  10. Serruys P, et al. N Engl J Med. 2010;363:136-146. Zanchin C. et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Note: 0.3% is the highest definite stent thrombosis rate.
  11. Stone G, et al. N Engl J Med. 2019;381:1820-1830.
  12. Teeuwen K, et al. JACC Cardiovasc Interv. 2017;10:133-143.
  13. Lam MK, et al. Am Heart J. 2015;169:69-77.
  14. Kaul U, et al. EuroIntervention. 2017;13:1194-1201.
  15. Sabaté M, et al. Lancet. 2016;387;357-366.
  16. Watanabe H, et al. JAMA. 2019;321(24):2414-2427.
  17. Valgimigli M, et al. BMJ. 2014;349:g6427.

 

MAT-2101789 v2.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
Abbott logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-2001111 v7.0

Disclaimer

You are about to enter an Abbott country- or region-specific website. 

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

Do you wish to continue and enter this website? 

YES

MAT-2305078 v1.0